Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Statins’ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Chrysoula Boutari, Panagiotis D. Pappas, Dimitrios A. Anastasilakis, et al.
Clinical Nutrition (2022) Vol. 41, Iss. 10, pp. 2195-2206
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

MAFLD as part of systemic metabolic dysregulation
Jing Zhao, Lu Liu, Yingying Cao, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 834-847
Closed Access | Times Cited: 14
Metabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System
Antonis A. Manolis, Theodora A. Manolis, Apostolos Vouliotis, et al.
Trends in Cardiovascular Medicine (2025)
Closed Access | Times Cited: 4
Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
J Bernhard, L Galli, Walter S. Speidl, et al.
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Open Access | Times Cited: 2
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
Anders Mellemkjær, Mikkel Breinholt Kjær, David Haldrup, et al.
European Journal of Internal Medicine (2023) Vol. 122, pp. 28-34
Open Access | Times Cited: 34
Management of metabolic-associated fatty liver disease: The diabetology perspective
Mohammad Sadiq Jeeyavudeen, Shahanas K A Khan, Sherouk Fouda, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 1, pp. 126-143
Open Access | Times Cited: 32
Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy?
Amirhossein Sahebkar, Zahra Foroutan, Niki Katsiki, et al.
Metabolism (2023) Vol. 146, pp. 155659-155659
Closed Access | Times Cited: 30
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Inês Domingues, Isabelle Leclercq, Ana Beloqui
Journal of Controlled Release (2023) Vol. 363, pp. 415-434
Closed Access | Times Cited: 27
A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
Shiqin Zhang, Xiaoling Ren, Bingzheng Zhang, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1859-1859
Open Access | Times Cited: 12
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
Xin Ding, Xu He, Bulang Tang, et al.
Chinese Medicine (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 9
Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: A 16S rRNA and non-targeted metabolomics analyses
ShaoPeng Wang, Xin Li, Bo Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116405-116405
Open Access | Times Cited: 7
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, et al.
Hepatology International (2025)
Closed Access
Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Thaninee Prasoppokakorn
Livers (2025) Vol. 5, Iss. 1, pp. 4-4
Open Access
Application of Generative Artificial Intelligence in Dyslipidemia Care
Fernando Bril, Gabriela Berg, Magalí Barchuk, et al.
Journal of Lipid and Atherosclerosis (2025) Vol. 14, Iss. 1, pp. 5-5
Open Access
Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Fernando Bril, Gabriela Berg, Magalí Barchuk, et al.
Journal of Lipid and Atherosclerosis (2025) Vol. 14, Iss. 1, pp. 69-69
Open Access
The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus
Mehmet Akif Parlar, Hakan Mutlu, Betül Doğantekin, et al.
Diagnostics (2025) Vol. 15, Iss. 4, pp. 426-426
Open Access
Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation
José A. Inia, Geurt Stokman, Elsbet J. Pieterman, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7818-7818
Open Access | Times Cited: 12
Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis
Xingfen Zhang, Dandi Lou, Rongrong Fu, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 6, pp. 762-775
Open Access | Times Cited: 9
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, et al.
Medicina (2023) Vol. 59, Iss. 10, pp. 1789-1789
Open Access | Times Cited: 9
Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries
Daniel B. Rosoff, Andrew S. Bell, Josephin Wagner, et al.
Cellular and Molecular Gastroenterology and Hepatology (2023) Vol. 17, Iss. 1, pp. 29-40
Open Access | Times Cited: 8
Metabolic-Associated Fatty Liver Disease and Diabetes
Nitin Kapoor, Sanjay Kalra
Endocrinology and Metabolism Clinics of North America (2023) Vol. 52, Iss. 3, pp. 469-484
Closed Access | Times Cited: 7
G-Protein-Coupled Receptor 120 Agonist Mitigates Steatotic and Fibrotic Features Triggered in Obese Mice by the Administration of a High-Fat and High-Carbohydrate Diet
Simona Pompili, Alfredo Cappariello, Antonella Vetuschi, et al.
ACS Omega (2024) Vol. 9, Iss. 29, pp. 31899-31909
Open Access | Times Cited: 2
Statin use and development and progression of non-alcohol fatty liver disease based on ultrasonography: a cohort study
Baoyu Feng, Fengde Li, Yanqi Lan, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 2
Expanding diagnostic and therapeutic horizons for MASH: Comparison of the latest and conventional therapeutic approaches
Georgia Anastasiou, Konstantinos Stefanakis, Michael A. Hill, et al.
Metabolism (2024), pp. 156044-156044
Closed Access | Times Cited: 2
Role of liver sinusoidal endothelial cells in the diagnosis and treatment of liver diseases
Anabel Fernández‐Iglesias, Jordi Gracia‐Sancho
Elsevier eBooks (2024), pp. 467-481
Closed Access | Times Cited: 1
Impact of Rosuvastatin on Metabolic Syndrome Patients with Moderate to Severe Metabolic Associated Fatty Liver Disease without Overt Diabetes: A Randomized Clinical Trial
Xuan Wang, Lu Lyu, Wei Li, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 9, pp. 103126-103126
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top